LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Cerrado

Sector Salud

16.09 -0.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

15.75

Máximo

16.11

Métricas clave
By Trading Economics
Ingresos	17M 33M
Ventas	36M 242M
BPA	0.2
Margen de beneficio	13.797
Empleados	597
EBITDA	12M 33M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+67.58 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	119M 2.7B
Apertura anterior	16.71
Cierre anterior	16.09

Noticias sobre sentimiento de mercado

By Acuity

100%

340 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

15.69 / 16.33 Soporte y Resistencia

ACADIA Pharmaceuticals Inc Gráfico

Noticias Relacionadas

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept 2024, 18:15 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept 2024, 18:12 UTC

Principales Noticias

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept 2024, 17:44 UTC

Charlas de Mercado

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept 2024, 17:30 UTC

Charlas de Mercado

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept 2024, 17:30 UTC

Principales Noticias

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept 2024, 17:27 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept 2024, 17:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 sept 2024, 17:00 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in August -- Market Talk

6 sept 2024, 16:36 UTC

Charlas de Mercado

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept 2024, 16:35 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept 2024, 16:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept 2024, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

6 sept 2024, 16:20 UTC

Ganancias

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept 2024, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

67.58% repunte

Estimación a 12 meses

Media 26.93 USD 67.58%

Máximo 39 USD

Mínimo 17 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

15.69 / 16.33Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

340 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).